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Abstract
Nitric Oxide (NO) plays a critical role in diverse physiological and pathological processes. We
show that a hypomorphic mouse model of argininosuccinate lyase (Asl) deficiency exhibits a
distinct phenotype manifest by multi-organ dysfunction and NO deficiency. Loss of Asl leads to
reduced NO synthesis due to decreased endogenous arginine synthesis as well as reduced
utilization of extracellular arginine for NO production in both humans and mice. Hence, ASL as
seen in other species through evolution has a structural function in addition to its catalytic activity.
Importantly, therapy with nitrite rescued the tissue autonomous NO deficiency in hypomorphic
Asl mice, while a NOS independent NO donor restored NO-dependent vascular reactivity in
subjects with ASL deficiency. Our data demonstrate a previously unappreciated role for ASL in
NOS function and NO homeostasis. Hence, ASL may serve as a target for manipulating NO
production in experimental models, as well as treatment of NO-related diseases.
L-Arginine is the natural substrate of nitric oxide synthases (NOS) for generating nitric
oxide (NO). As a by-product of the NOS reaction, L-citrulline is formed from L-arginine.
Within the cell, citrulline can be recycled back to arginine by the cytoplasmic enzymes
argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL), constituting the
citrulline-NO cycle (Supplementary Fig. 1). The availability of intracellular arginine is
potentially a rate-limiting factor in cellular NO production in spite of the fact that the
extracellular and exogenous sources should theoretically be able to replenish its deficiency.
It has been hypothesized that compartmentalization and intracellular metabolite channeling
underlies the “arginine paradox” in which extracellular and intracellular pools of arginine
are distinguishable. However, this has yet to be proven in vivo and the mechanistic basis is
unknown.
Many tissues and cell types contain the cytoplasmic enzymes, ASS and ASL, providing a
cell-autonomous mechanism for generating arginine (Supplementary Fig. 1). Arginine
serves as the precursor for the synthesis of urea, NO, polyamines, proline, glutamate,
creatine and agmatine1. The regulation of L-arginine availability for these intracellular
pathways is cell-type and end-product specific, e.g., arginine generated by ASL in
hepatocytes is mostly directed to urea production, while in other cell types its metabolic fate
is context dependent2.
Argininosuccinic aciduria (ASA) (MIM 207900) is the second most common human urea
cycle disorder (UCD) and is caused by deficiency of ASL. Subjects with ASA disease
cannot generate arginine from citrulline. It is noteworthy that despite early treatment and
adequate metabolic control of hyperammonemia, subjects with ASA disease can exhibit
persistent intellectual impairment, delayed motor skills3,4 and progressive hepatic
disease5–7. Importantly, intellectual impairment and liver cirrhosis are seen even in those
with early initiation of treatment and few, if any documented episodes of hyperammonemia.
Recent experience also suggests that patients are at risk for the development of systemic
hypertension4,8,9. The mechanism behind these unique clinical features that are not observed
in other UCDs is open to speculation, although a reduction of NO production secondary to a
localized deficiency of L-arginine is one intriguing possibility. An association between urea
cycle function and NO production has been previously suggested by the association of
genetic variants in urea cycle genes with NO-related disease processes10,11. Recently, NO
synthesis was evaluated in patients with UCD12. However, no mechanism was demonstrated
that could explain potential differences amongst or between patients and controls. Such a
study emphasizes the difficulties in studying NO metabolism at the level of the whole
organism in non-steady state conditions.
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We hypothesized that a cell autonomous deficiency of ASL would lead to systemic NO
deficiency. In addition, because of the inability of supplemental arginine to prevent long-
term complications in ASA patients, we investigated whether ASL plays a more central role
in cellular arginine utilization for NO synthesis beyond intracellular recycling of citrulline
into arginine. We tested our hypothesis in vivo in a hypomorphic mouse model of Asl as
well as in ASA subjects with absent enzyme activity. Our results were complemented with
in vitro studies in human ASA fibroblasts, in primary cell lines with ASL knockdown, and
in cells over expressing ASL mutants that are enzymatically inactive but structurally intact.
RESULTS
Asl hypomorphic mice show evidence of multi-organ dysfunction
We hypothesized that loss of Asl would cause deficiency of endogenous arginine production
resulting in reduced NO synthesis. Similar to human neonates with ASA, complete loss of
function of Asl in mice leads to neonatal hyperammonemia and lethality13. Therefore, we
generated a conditional hypomorphic allele by introducing a Neomycin (Neo) selection
cassette into intron 9 of the mouse Asl gene (Supplementary Fig. 2a–c). As predicted,
quantitative RT-PCR, Western blot analysis and Asl enzymatic activity of mice homozygous
for the Neo insertion, AslNeo/Neo, demonstrated significant reduction in gene and protein
expression with 25% residual RNA, 25% residual protein and 16% residual enzyme activity,
thus confirming the hypomorphic nature of this allele (Supplementary Fig. 3a–c).
Biochemically, plasma amino acid analysis also showed a profile consistent with Asl
deficiency with elevation of citrulline and argininosuccinic acid, two precursor metabolites
upstream of the enzymatic block, and reduction of arginine, a product metabolite
downstream of the enzymatic block (Supplementary Fig. 3d). The hypomorphic nature of
this allele was confirmed to be due to the Neo cassette insertion, as its Frt-mediated deletion
resulted in phenotypically normal mice (AslFlox/Flox) (Supplementary Fig. 4a).
Asl hypomorphic mice were born at the expected Mendelian ratio but die within the first 3–4
weeks of life from multi-organ failure (Fig. 1a,b), providing an opportunity to explore the
consequences of impaired endogenous arginine synthesis. During the early postnatal period,
the dietary supply of arginine (from breast milk) is insufficient and thus, there is dependency
on endogenous arginine synthesis14.
While AslNeo/Neo mice were indistinguishable from wild type littermates at birth, they
showed abnormal hair patterning and significant growth restriction by two weeks (Fig 1a,c).
AslNeo/Neo mice also displayed evidence of multi-organ dysfunction characterized by
elevation of liver transaminases, decreased renal creatinine clearance, and elevated systolic
and diastolic blood pressures as compared to WT animals (Fig. 1d–f). Histological analyses
revealed multi organ involvement, including the immune, hematopoietic, renal and
cardiovascular systems, features that are not attributable to hyperammonemia15
(Supplementary Figure 5a–f).
We noted that some features of this phenotype would be consistent with a systemic
disruption of NO homeostasis, since NO has been shown to play an important role in diverse
pathological processes including systemic hypertension, immune dysfunction, renal disease
and hepatic fibrosis16,17.
Loss of Asl leads to global NO deficiency in mice
To determine whether the physiological features observed in the Asl hypomorphic mice
were attributable to impaired NO synthesis or altered NO homeostasis, we examined the
effect of a genetic interaction between Asl and Nos3 on systemic blood pressure. While
Erez et al. Page 3
Nat Med. Author manuscript; available in PMC 2012 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
neither the Nos3+/− or the AslNeo/+ mice are hypertensive, the double heterozygous mice,
Nos3+/−;AslNeo/+ had significant hypertension (Figure 1g) confirming an epistatic effect.
While measurement of NO oxidative products (nitrite, nitrate) can reflect the status of NO
production, we additionally assayed the tissue and plasma nitrosothiols (RSNO) levels as a
reflection of NO production and signaling. We found reduced NO production in tissues of
AslNeo/Neo mice as reflected by a significant decrease in S-nitrosylation and/or nitrite in
heart, and other tissues (Fig. 2a,b). To address whether the loss of Asl led to secondary
changes within the NO pathway that might alternatively account for reduced NO synthesis,
we measured RNA and protein expression levels of Ass (upstream of Asl), arginine
transporter Cat-1, and Nos3. We found that their expression in mutant lung and liver was
either unchanged or even up-regulated in the face of Asl loss of function (Fig. 2c,
Supplementary Fig. 6a–c). Similarly, the levels of the endogenous inhibitor of L-arginine,
asymmetric dimethyl arginine (ADMA), were also comparable in mutant and WT mice
(Data not shown).
Hence, the multi-organ dysfunction observed in Asl mutant mice correlated with evidence of
decreased systemic NO resulting specifically from the primary deficiency of Asl activity.
This specificity was further supported by the finding of normal tissue RSNO levels in the
AslFlox/Flox mice in which the Neo cassette had been excised and Asl expression normalized
(Supplementary Fig. 4b,c).
Treatment with alternative NO sources partially rescues Asl hypomorphic mice
Recent studies show that nitrate and nitrite can be recycled to form NO as an alternative to
the classical L-arginine-NOS pathway18,19. If some of the phenotypic consequences of Asl
deficiency were due to decreased NO production, normalization of NO status by
supplementation with sodium nitrite should partially correct the phenotype. However, in this
model, hyperammonemia (secondary to an inability to clear waste nitrogen by urea synthesis
in the liver) complicates the postnatal picture and contributes to the lethality in AslNeo/Neo
mice. Therefore, we first treated Asl mutant animals with either sodium benzoate (250 mg
kg−1 per day) or with L-arginine (100 mg kg−1 per day). These medications are the standard
of care in ASA patients for prevention of hyperammonemia. The former works by
stimulating alternative disposal of glycine containing nitrogen via conjugation, and the latter
works by priming the urea cycle to generate more ASA as a nitrogen sink that is cleared via
urinary excretion. Not surprisingly, we found significantly improved survival in AslNeo/Neo
mutant mice treated with these drugs suggesting that, similar to human patients,
hyperammonemia is indeed partially responsible for early lethality in this model (Fig. 3a).
Survival improved more with arginine treatment than sodium benzoate treatment suggesting
that exogenous arginine may also have a salutary effect on NO deficiency state in addition to
its effects on nitrogen clearance. However, the predominant contribution of NO deficiency
to the phenotype was best evidenced by the observation that treatment with sodium nitrite,
which can be metabolized to form NO18,19, produced the greatest survival among all treated
groups (Fig. 3a, Supplementary Table 2). Nitrite supplementation produced comparable
survival to the traditional treatment of sodium benzoate plus arginine; however, weight gain
was only evident in the nitrite group (Fig. 3b,c). Importantly, combination triple therapy
with sodium benzoate, arginine, and sodium nitrite, produced the greatest survival and
weight gain (Fig. 3b,c). Moreover, triple therapy was associated with correction of liver
protein nitrosylation to levels higher than those observed in the WT mice and led to
normalization of the blood pressures in mutant mice (Fig. 3d,e).
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Tissue and cellular NO deficiency despite adequate arginine treatment
To evaluate for NO insufficiency at a tissue level in AslNeo/Neo mice, we performed classic
aortic ring relaxation measurements. In contrast to WT mice, aorta from AslNeo/Neo mice
exhibited evidence of significant endothelial dysfunction as shown by an inability of
preconstricted aortic rings to relax in response to acetylcholine (Fig. 3f,g). Furthermore,
neither preconstricted aortic rings from WT nor AslNeo/Neo mice responded to arginine
treatment. A lack of response in WT rings ex vivo was expected as the vascular tissues are
saturated with arginine to levels higher than the Km values of NOS for NO production20–22.
However, this result was surprising in the AslNeo/Neo mouse aortas given their low
intracellular levels of arginine. In contrast, AslNeo/Neo preconstricted aortic rings relaxed in
response to sodium nitroprusside, a NOS independent NO donor, demonstrating the integrity
of the vascular preparation and a functional signaling pathway downstream of NO (Fig. 3g).
To further evaluate the requirement of Asl for NO synthesis in a cell specific manner, we
knocked down its expression using RNAi in primary piglet endothelial cells (Figure 4a,b).
We found that decreased levels of ASL led to significantly lower levels of nitrite production
in response to inducers such as bradykinin and L-arginine (Figure 4c,d).
Together, these data underscore the requirement for Asl in the production of NO at the
organism, tissue, and cellular levels.
ASL mutant cells and ASA patients have deficiency of NOS-dependent NO production
Our findings from the hypomorphic mouse model and in vitro studies predict that human
ASA patients should also be deficient for markers of NO synthesis in spite of normal or
even elevated levels of extracellular plasma arginine from therapeutic arginine
supplementation provided as “standard of care”. To assess the role of ASL in NO synthesis
in humans, we studied fibroblasts from human subjects with ASA disease with null ASL
enzymatic activity. First, we verified that primary human fibroblasts express both NOS3 and
NOS2 (Supplementary Fig. 7a). Although the expression levels of both NOS2 and NOS3 are
lower than those seen in endothelial cells, both isoforms were detected at comparable levels
in cultured human fibroblasts (Supplementary Fig. 7a). In addition, as previously
published23–25, we established that NOS is functional in primary fibroblasts and that it can
be activated by BH4 and inhibited by a NOS inhibitor (Supplementary Fig. 7b). As predicted
from our mouse and cell data, addition of either L-arginine (1000µM) or L-citrulline to the
media of primary fibroblasts from control subjects for either 30 minutes or 24 hours resulted
in significant increases in nitrite and cGMP production reflecting an increase in NO
synthesis from NOS. In contrast, nitrite production, nitrosylation, and cGMP production in
fibroblasts from subjects with ASA did not increase in response to L-arginine treatment
despite similar expression of NO synthetic proteins (Fig. 5a,b and Supplementary Fig. 7c–f).
The viability of cells from both controls and subjects with ASA disease cells was
comparable and intracellular arginine levels were effectively increased in both cell types by
supplementation (Data not shown) and yet, normal NO synthesis did not occur in the
absence of ASL.
Deficiency of arginine utilization for NO synthesis in subjects with ASA
In spite of elevations in plasma arginine (as a consequence of therapeutic supplementation)
and of citrulline (that accumulates upstream of the block), subjects with ASL deficiency had
significantly decreased levels of plasma RSNO and decreased nitrite as compared to healthy
control subjects (Fig. 5c). In order to directly measure NO production and trace the
contribution of extracellular arginine to NO conversion, we performed stable isotopic flux
measurements in control and ASA subjects on a steady state nitrite and protein restricted
diet. Using a two-day multi-tracer protocol, we found increased arginine and urea
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appearance (flux) rates in ASA subjects that are attributable to pharmacological treatment
with L-arginine (Fig. 5d-Left Panel). We also found increased citrulline flux and fractional
transfer of 15N label from 15N-glutamine to 15N-citrulline that is explained by the
accumulation of this metabolite upstream of the block in ASL deficiency. However,
consistent with the decreased plasma RSNO levels and the mouse and cellular data, we
found dramatically decreased 15N transfer from infused 15N2-guanidino-labelled-arginine
to 15N-citrulline, a surrogate marker for NO production (Fig. 5d-Right Panel). Hence,
dynamic measurements of metabolite fluxes reveal that in spite of high extracellular arginine
and citrulline fluxes, ASA subjects have dramatically decreased transfer of guanidino
nitrogen from arginine to citrulline, a marker of NO production from arginine. Our data
suggest that the decrease in NO production is attributable to an inability both to recycle
intracellular citrulline into arginine for endogenous synthesis, and to channel extracellular
plasma arginine for NO production. These complementary human data further support our
finding, that in the absence of ASL, extracellular arginine (the source of the isotopic label) is
inefficiently converted to citrulline to form NO. Hence, ASL deficiency is a model of
deficient NO synthesis from both intracellular and extracellular sources of arginine.
To evaluate the functional consequences of this observation in vivo, we performed vessel
reactivity assays in human subjects with ASA. We examined the vasodilatory response of
the brachial artery via Doppler ultrasound following transient occlusion of flow as a measure
of NOS-dependent vascular relaxation, and then the vasodilator response following
sublingual nitroglycerin as a measure of NOS-independent vascular relaxation (Fig. 5e). In
healthy controls, vascular dilatation following both steps were equivalent and the magnitude
of response was similar to previously reported responses26. In contrast, subjects with ASA
disease failed to show any NOS-dependent vascular relaxation after release of vessel
occlusion. However, they responded similarly to controls after administration of sublingual
nitroglycerin (Fig. 5e) showing normal response to an exogenous, NOS-independent source
of NO. These results are significant as the near absence of flow-mediated relaxation, a
measure of NO mediated dilation, has not been reported in other pediatric diseases.
Importantly, these results in human subjects corroborate with the aortic ring experiments in
the hypomorphic Asl mouse model and support that while the signaling downstream of NO
is intact, loss of ASL limits NOS-dependent NO production, leading to loss of NOS-
dependent vascular reactivity.
ASL is required for maintenance of a NOS multi-protein complex
Direct biochemical interaction within a compartmentalized NOS complex may explain
metabolite channeling27,28. The three key protein components responsible for recycling
citrulline into NO are ASS, ASL, and NOS and their expressions are coordinately
regulated29. Several studies have shown either interaction or colocalization amongst these
three proteins30,33. Interestingly, an interaction between NOS3 and the cationic amino acid
transporter CAT-1 responsible for arginine transport, was also recently described in
endothelial cells30.
We first verified the interaction between the proteins involved in the complex by performing
a mass spectrometry analysis of immunoprecipitate using an antibody to ASS on LPS
induced RAW246.7 cells, which confirmed the existence of this complex for Nos2
(Supplementary Table 1). We expanded upon these findings by testing the existence of a
complex between the protein components involved in NO synthesis by performing
immunoprecipitation using antibody to ASS in lung and brain tissues from WT mice. Our
results support the existence of a NOS-containing multi-protein complex for both NOS
isoforms i.e., Nos3 in lung and Nos1 in brain (Fig. 6a, Supplementary Figure 8).
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To determine the effects of partial loss of Asl on this protein complex, we quantified the
component proteins co-immunoprecipitated by antibody to ASS in WT vs. AslNeo/Neo mice.
Since ASA patients have hypertension and intellectual delays that are unique and
independent of hyperammonemic episodes, we focused our studies on the effect of Asl
deficiency on its complex formation with Nos3 and Nos1. AslNeo/Neo mouse lung and brain
showed significantly decreased quantities of both Nos3 and Nos1 isoforms, respectively, as
well as other proteins involved in the complex (Fig. 6a, Supplementary Fig.8); this is despite
increased abundance of the individual components (other than Asl) in tissues of AslNeo/Neo
mice compared to WT on Western analysis (Figure 2c, Supplementary Fig.8). These data
support a central requirement for Asl in the formation of this complex.
To dissect the structural requirement of ASL for NOS complex formation from its catalytic
activity, we tested NOS complex assembly using human ASL mutants in its catalytic site
R236W31 (Fig. 6b). This mutation abolishes the enzymatic activity of ASL, i.e., the
recycling of intracellular citrulline via the cleavage of ASA, but does not abolish its tertiary
structure. Indeed, in vitro over-expression of mutated ASL in COS7 cells did not prevent
NOS protein assembly with ASS as shown by IP using antibodies against ASS or NOS.
However, consistent with our finding in the AslNeo/Neo mouse, absence of ASL prevented
efficient immunoprecipitation of the proteins involved in the NOS complex by either one of
these antibodies (Fig. 6b).
To test whether this structural requirement for ASL in NOS complex formation is in fact
required for utilization of extracellular arginine for NO production, we transduced ASA
mutant fibroblasts null for ASL activity with lentivirus expressing either wild type human
ASL or with human ASL mutated in the catalytic domain R113Q31. As extensively studied
by others, the R113Q similarly abolishes the catalytic activity of ASL without affecting ASL
protein stability31,32. If the structural requirement of this NOS complex is required for
channeling of extracellular arginine to NOS, the catalytic site mutation would be expected to
restore NO production in response to extracellular arginine in ASA mutant cells. Indeed,
when we overexpressed human ASL with the R113Q mutation in vitro, ASA fibroblasts
were able to generate nitrite at a level comparable to control cells when supplemented with
arginine (Figure 6c).
This structural requirement for an ASL-dependent NOS complex begins to explain our
physiological and cellular observations, suggesting that in the absence of ASL, there is a less
efficient formation of a NOS multi-protein complex leading to decrease NO production from
both endogenously synthesized and exogenously channeled arginine (Fig. 6d).
DISCUSSION
Our findings support a requirement for ASL not only to synthesize intracellular arginine, but
also to utilize extracellular arginine for NOS-dependent NO synthesis. We demonstrate an
intracytosolic complex of proteins important for nitric oxide synthesis to explain the
structural basis for metabolite channeling that reconciles the phenotypes observed in human
and mouse models of ASL deficiency. While likely not the only explanation, the data
support that decreased ASL levels leads to loss of NOS complex formation that is associated
with NO deficiency at the whole organism, tissue and cellular levels in both humans and
mice.
This conclusion is based on a combination of mouse and human studies that were prompted
by clinical observations in ASA patients. First, the natural history of ASL-deficient humans
with argininosuccinic aciduria suggested the presence of organ dysfunction and
complications that were independent of hyperammonemia caused by hepatic urea cycle
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deficiency. This led us to hypothesize alternative mechanisms of injury including deficiency
of NO secondary to loss of citrulline recycling or endogenous arginine production.
However, this could not alone explain the phenotypic complexity because ASL patients are
replete with extracellular arginine due to pharmacological supplementation.
This apparent conundrum was evident in the hypomorphic mouse model of Asl deficiency,
where we observed histological evidence of multi-organ dysfunction that correlated with
biochemical evidence of systemic NO deficiency. This was further supported by the finding
of decreased markers of NO production (plasma RSNO and nitrite) in ASA patients.
Importantly, ASA patients, ASA fibroblasts, and primary endothelial cells made deficient of
Asl by siRNA knockdown, were also unable to efficiently generate NO after extracellular
arginine supplementation. In humans, this was demonstrated via dynamic measurement of
arginine to citrulline flux; while in cells, it was demonstrated via measurement of nitrite and/
or cGMP. This NO deficiency was found to be tissue autonomous as preconstricted aortic
rings from mutant mice relaxed in response to NO donors but not arginine, while ASA
subjects exhibited abnormal flow-mediated vascular relaxation that was restored by
nitroglycerin. On the whole organism level, provision of an NOS independent source of NO
in the form of nitrite therapy significantly prolonged survival of hypomorphic mice while
also restoring tissue nitrosylation and normalizing blood pressure.
The NO deficiency was caused in part by the inability of patients and cells to efficiently
generate intracellular arginine or to utilize extracellular arginine for NO production in the
face of ASL deficiency. This was in spite of adequate expression of all other protein
components necessary for NO production including the arginine transporter CAT-1, ASS,
HSP90, and NOS. This observation correlated with the existence of a NOS complex that
depends on the structural, but not enzymatic function of ASL. Loss of ASL was associated
with decreased abundance of this complex, decreased utilization of arginine for NO
production, and functional consequences of NO deficiency at the organ and cellular levels.
This structural requirement was supported by the ability of specific mutations in the ASL
catalytic domain to participate in the NOS complex while the complete absence of ASL
prevented efficient complex formation. Together, these studies distinguish two essential
roles for ASL: the recycling of citrulline in the cell for cell autonomous arginine synthesis,
and the maintenance of a NOS complex that is required for efficient NO production from
extracellular sources of arginine. The former depends on the catalytic function of ASL,
while the latter requires its structural integrity. Interestingly, this is consistent with the
distinct evolutionary roles of ASL in other species33. Since in cell, mouse, and patient
models, the NO deficiency are evidenced in the face of excess arginine, it is likely that the
primary dysfunction is at the level of the NO metabolon where insufficient channeling of
arginine due to loss of the ASL-NOS complex leads to secondary decreased NO production.
An important question for future study is whether the loss of arginine channeling leads to
NOS uncoupling and consequent increase in free radical stress.
Clinically, these data suggest that the vascular dysfunction and intellectual delay seen in
ASA patients may be partly due to NO insufficiency, and hence, treatment with a NOS-
independent source of NO, e.g., sodium nitrite, or NO donors, would be beneficial in the
long term. Moreover, the clinical variability seen in ASA patients may depend on the
differential effects of specific mutations on catalytic vs. structural functions.
These data also have broader implications for NO biology and disease. Mechanistically, they
support intracellular compartmentalization as an explanation for the “arginine paradox”, i.e.,
the increased production of NO with the addition of extracellular arginine despite apparently
saturating intracellular arginine levels. Moreover, they suggest an explanation as to why the
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arginine paradox is not observed with ASL deficiency. As such, ASL may serve as the
linchpin in NO production. Hence, inhibition of ASL in a cell-specific fashion may be an
effective way to probe NO function in vivo, independent of potential NOS redundancy.
Similarly, it may serve as a novel target for manipulating NO production in a cell
autonomous fashion in human disease processes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Physiological phenotype of AslNeo/Neo mice
(a) Growth and hair phenotype. (b) Kaplan Meier survival curve for AslNeo/Neo mice (n=22;
solid line) vs. WT mice (n=19; dotted line) (*p<0.002). (c) Weight for AslNeo/Neo mice
(n=5) vs. WT (n=4) or heterozygous (n=6) littermates. WT: wild type; AslNeo/+:
heterozygous mice; AslNeo/Neo: homozygous mice (*p<0.05). (d) Renal Function for
AslNeo/Neo mice (n=4) vs. WT littermates (n=5) (*p<0.005). (e) Liver transanimases for
AslNeo/Neo mice (*p<0.05). (f) Blood pressure measurements for AslNeo/Neo mice (n=6) vs.
WT littermates (n=4) (*p<0.0002). (g) Blood pressure in Nos3+/−;AslNeo/+ (n=9) double
heterozygous vs. Nos3+/−;Asl+/+ mice (n=4) (**p<2×10−8).
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Figure 2. Decreased NO production with ASL deficiency
(a,b) Nitric oxide status in AslNeo/Neo mice (n=3) and WT littermates (n=5). (a) Nitrosothiol
measurements (RSNO) (*p<0.05). (b) Nitrite measurements (*p<0.05). (c) Representative
Western Blot analyses of lung tissue samples from 10 AslNeo/Neo mice and 10 WT control.
Antibodies used are labeled on side. Protein densitometry is shown in the bottom panel.
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Figure 3. Pharmacological rescue with an NO source
(a) Kaplan Meier survival curves comparing different treatment modalities vs. placebo in
AslNeo/Neo mice (*p<0.007) (n = 15–22 in each group). (b) Kaplan-Meier survival analysis
(*p<0.001 on log ranks) between the arginine plus sodium benzoate treated group (n=16),
the sodium nitrite treated group (n=27) and the triple therapy group (n=22), when compared
to the placebo group (n=22). (c) Left panel: Weight gain with sodium nitrite treatment
(n=29) and the triple therapy treatment (n=22) as compared to placebo (n=26) and to the
standard treatment with arginine and sodium benzoate (n=17) group (one-way ANOVA, *p
<0.05). Right panel: A representative picture of WT control and AslNeo/Neo mice at 8 weeks
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of age after receiving the triple therapy. (d) Nitrosothiols (RSNO) were measured in liver of
AslNeo/Neo and WT mice treated with placebo vs. triple therapy (arginine, sodium nitrite and
sodium benzoate) (*p<0.01; **p<0.009). (e) Blood pressure measurements in WT (n=3) vs.
AslNeo/Neo (n=4) on triple therapy with sodium benzoate, arginine, and sodium nitrite. (f,g)
Aortic ring relaxation. (f) A representative graph for the difference in WT aortic rings
relaxation vs. AslNeo/Neo aortic rings relaxation (p<0.004). The graph represents the
percentage relaxation in response to acetylcholine measured in 3 WT and 3 AslNeo/Neo
aortae, 4 segments from each aorta were analyzed (p<0.004). (g) Representative tracing
from WT vs. AslNeo/Neo aortic ring isometric tension studies showing percentage relaxation
in response to acetylcholine (Ach), arginine (Arg), and sodium nitroprusside (SNP)
treatment
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Figure 4. Asl knockdown in piglet endothelial cells decreases nitrite production in response to
arginine
(a) Relative RNA expression in pooled RNA from primary piglet pulmonary artery (PA)
endothelial cells transfected with Asl siRNA (ASL-RNAi) compared to non-specific siRNA
(NS-RNAi). Endothelial specific von Willebrand factor (vWF) and NOS3 levels are shown
as control. (b) Western blot using antibody to ASL in endothelial cells transfected with ASL
siRNA as compared to NS-RNAi siRNA. The densitometric quantification is below. (c)
Measurement of the relative nitrite levels in the media of piglet PA endothelial cells
transfected with ASL siRNA vs. NS siRNA in response to Bradykinin (10 µM) treatment
(for 24 hours) with and without the NOS inhibitor L-NAME (100 µM) (*p<0.05). The
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experiment was performed in triplicate. Please refer to the online methods for the specific
calculation (d) Measurement of the relative nitrite levels in the media of piglet PA
endothelial cells transfected with ASL siRNA vs. NS siRNA in response to L-Arginine (10
mM) treatment (for 60 minutes) with and without L-NMMA (500 µM) or D-Arginine as
control (*p< 0.01, **p<0.005). The experiment was performed in triplicates. NS: Non-
significant.
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Figure 5. ASL deficient human cells and patients do not efficiently generate NO from arginine
(a) RSNO production (ΔRSNO) in control vs. ASA fibroblasts supplemented with L-
arginine (1 mM) for 24 hours (*p<0.05). (b) Nitrite production (ΔNitrite) in control vs. ASA
fibroblasts in response to listed treatments over 30 minutes (ANOVA, *p<0.05
**p<0.0005). (c) Human ASA subjects (n=3) plasma arginine, citrulline, nitrite and RSNO
levels as compared to controls. (*p<0.05 **p<0.005 ***p<0.0005). (d) Dynamic metabolite
flux measurements in ASA vs. control subjects. Left panel: Arginine and urea flux in ASA
subjects (n=3) vs. controls (n=3). Right panel: Citrulline flux, fractional transfer of the
amido-nitrogen from 15N-glutamine to 15N-citrulline, and fractional transfer of guanidine
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nitrogen from 15N2-arginine to 15N-citrulline (a marker of NO production) in ASA subjects
compared to controls, (GLN-Glutamine; CIT- Citrulline, ARG- Arginine) (*p<0.05
**p<0.005 ***p<0.0005 **** p<0.00005). (e) Brachial artery (BA) mean percentage
vasodilatation measured using Doppler ultrasound. Left Panel: NOS dependent flow
mediated relaxation. The green dashed line represents the lower normal limit for vessel
dilation (*p<0.05). Right Panel: NOS independent relaxation stimulated by 0.4 mg of
sublingual nitroglycerin. ASA subjects (n=2), controls (n=3). BA - Brachial Artery; NTG -
nitroglycerin.
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Figure 6. ASL is required to maintain an NO synthetic complex
(a) Immunoprecipitation with antibody to ASS and subsequent immunoblots (IB) with listed
antibodies of lung protein lysates from AslNeo/Neo (lanes 1–2) and WT mice (lanes 3–4)
(n=2 each). On the right is the densitometric quantification from 3 separate studies
performed from a total of 9 WT and 12 AslNeo/Neo mice (*p<0.05). (b,c) Effects of ASL
catalytic site mutations on complex formation and NO production. (b)
Immunoprecipitation with ASS and NOS3 antibodies of COS7 cells transfected with either
WT ASL or R236W ASL, empty plasmid or with GFP and NOS3. Left panel: A western
analysis showing expression of the ASL and NOS3. Right panel: Immunoprecipitation with
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antibody to NOS3 or to ASS followed by immunoblot as listed. The blots are representative
of three different experiments. (c) Nitrite production in response to arginine in ASA cells
expressing catalytically inactive ASL (*p<0.05). Left panel: Western blot showing the
expression of ASL in ASA null cells transduced with ASL R113W vs. control fibroblasts.
Right panel: Nitrite levels measured at 15 minutes with and without addition of arginine to
the medium (*p<0.05). (d) Model for the NOS complex in arginine channeling. Arginine
from de novo cellular synthesis by ASL or via transport from extracellular pools by CAT-1
can be channeled to NOS via ASL.
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